ZTlido Royalty Investors

ZTlido Royalty Investors is a special purpose vehicle (SPV) created to provide royalty-based financing for the commercialization of ZTlido (lidocaine topical system 1.8%). The entity holds the rights to receive a portion of the net sales of ZTlido, a product developed and marketed by Scilex Holding Company for the treatment of post-herpetic neuralgia. This financing structure allowed Scilex to secure non-dilutive capital to support its commercial operations and growth. As a dedicated investment vehicle, ZTlido Royalty Investors does not engage in drug discovery or clinical development but serves as a financial counterparty to the product's manufacturer. The underlying asset, ZTlido, is an FDA-approved topical patch designed with advanced adhesion technology to provide efficient drug delivery.